Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Komal L. Jhaveri, Lisa D. Eli, Hans P. M. W. Wildiers, Sara Alsterlind Hurvitz, Ángel Guerrero Zotano, Nisha G Unni and 24 more
- Rank
- 49 of 3,639
- Percentile
- top 1.4%
- Where
- Annals of Oncology, 2023
- Citations
- 72
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.